CN111588037A - Euphausia superba oil phospholipid oral liquid with high EPA/DPA (eicosapentaenoic acid/docosahexaenoic acid) - Google Patents
Euphausia superba oil phospholipid oral liquid with high EPA/DPA (eicosapentaenoic acid/docosahexaenoic acid) Download PDFInfo
- Publication number
- CN111588037A CN111588037A CN202010453551.9A CN202010453551A CN111588037A CN 111588037 A CN111588037 A CN 111588037A CN 202010453551 A CN202010453551 A CN 202010453551A CN 111588037 A CN111588037 A CN 111588037A
- Authority
- CN
- China
- Prior art keywords
- antarctic krill
- oral liquid
- phospholipid
- liquid
- krill oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims description 123
- 150000003904 phospholipids Chemical class 0.000 title claims description 96
- 241000239370 Euphausia superba Species 0.000 title claims description 43
- 235000020673 eicosapentaenoic acid Nutrition 0.000 title description 29
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 title description 16
- 235000020669 docosahexaenoic acid Nutrition 0.000 title description 14
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 title description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 title description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 title description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 title description 2
- 229940106134 krill oil Drugs 0.000 claims description 109
- 239000000243 solution Substances 0.000 claims description 108
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 81
- 239000003795 chemical substances by application Substances 0.000 claims description 61
- 239000000843 powder Substances 0.000 claims description 56
- 102000004190 Enzymes Human genes 0.000 claims description 54
- 108090000790 Enzymes Proteins 0.000 claims description 54
- 229940088598 enzyme Drugs 0.000 claims description 54
- 230000000813 microbial effect Effects 0.000 claims description 51
- 241000239366 Euphausiacea Species 0.000 claims description 50
- 238000002360 preparation method Methods 0.000 claims description 50
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 48
- 239000004365 Protease Substances 0.000 claims description 43
- 239000000287 crude extract Substances 0.000 claims description 41
- 238000000926 separation method Methods 0.000 claims description 41
- 238000003756 stirring Methods 0.000 claims description 41
- 238000001816 cooling Methods 0.000 claims description 40
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 39
- 150000001875 compounds Chemical class 0.000 claims description 39
- 238000002386 leaching Methods 0.000 claims description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- 238000001914 filtration Methods 0.000 claims description 38
- 239000004367 Lipase Substances 0.000 claims description 34
- 108090001060 Lipase Proteins 0.000 claims description 34
- 102000004882 Lipase Human genes 0.000 claims description 34
- 235000019421 lipase Nutrition 0.000 claims description 34
- 241000194107 Bacillus megaterium Species 0.000 claims description 33
- 108090000371 Esterases Proteins 0.000 claims description 31
- 108091005804 Peptidases Proteins 0.000 claims description 31
- 235000019419 proteases Nutrition 0.000 claims description 31
- 238000001035 drying Methods 0.000 claims description 27
- 230000001954 sterilising effect Effects 0.000 claims description 27
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 27
- 238000010564 aerobic fermentation Methods 0.000 claims description 26
- 230000036571 hydration Effects 0.000 claims description 26
- 238000006703 hydration reaction Methods 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 26
- 239000008213 purified water Substances 0.000 claims description 26
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 25
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 23
- 239000002131 composite material Substances 0.000 claims description 22
- 230000004151 fermentation Effects 0.000 claims description 22
- 244000063299 Bacillus subtilis Species 0.000 claims description 21
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 21
- 238000000855 fermentation Methods 0.000 claims description 20
- 241000589516 Pseudomonas Species 0.000 claims description 16
- 239000002994 raw material Substances 0.000 claims description 16
- 239000011259 mixed solution Substances 0.000 claims description 15
- 230000007935 neutral effect Effects 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 14
- 230000009849 deactivation Effects 0.000 claims description 13
- 239000000796 flavoring agent Substances 0.000 claims description 13
- 235000013355 food flavoring agent Nutrition 0.000 claims description 13
- 238000004108 freeze drying Methods 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 13
- 230000000415 inactivating effect Effects 0.000 claims description 13
- 238000004062 sedimentation Methods 0.000 claims description 13
- 238000007873 sieving Methods 0.000 claims description 13
- 239000002002 slurry Substances 0.000 claims description 13
- 238000001694 spray drying Methods 0.000 claims description 13
- 238000004659 sterilization and disinfection Methods 0.000 claims description 13
- 241001052560 Thallis Species 0.000 claims description 12
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 11
- 108090000526 Papain Proteins 0.000 claims description 10
- 102000004142 Trypsin Human genes 0.000 claims description 10
- 108090000631 Trypsin Proteins 0.000 claims description 10
- 108010007119 flavourzyme Proteins 0.000 claims description 10
- 235000019834 papain Nutrition 0.000 claims description 10
- 229940055729 papain Drugs 0.000 claims description 10
- 239000012588 trypsin Substances 0.000 claims description 10
- 239000001963 growth medium Substances 0.000 claims description 6
- 238000009630 liquid culture Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- 241000228212 Aspergillus Species 0.000 claims description 2
- 108090000145 Bacillolysin Proteins 0.000 claims description 2
- 108010004032 Bromelains Proteins 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 102000035092 Neutral proteases Human genes 0.000 claims description 2
- 108091005507 Neutral proteases Proteins 0.000 claims description 2
- 102000057297 Pepsin A Human genes 0.000 claims description 2
- 108090000284 Pepsin A Proteins 0.000 claims description 2
- 241000235527 Rhizopus Species 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 235000019835 bromelain Nutrition 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 235000021433 fructose syrup Nutrition 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 229940111202 pepsin Drugs 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 238000009423 ventilation Methods 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 3
- 102000035195 Peptidases Human genes 0.000 description 28
- 238000000605 extraction Methods 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000242757 Anthozoa Species 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 241000258957 Asteroidea Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000283216 Phocidae Species 0.000 description 1
- 241000243142 Porifera Species 0.000 description 1
- 241000287486 Spheniscidae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B1/00—Production of fats or fatty oils from raw materials
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B1/00—Production of fats or fatty oils from raw materials
- C11B1/02—Pretreatment
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B1/00—Production of fats or fatty oils from raw materials
- C11B1/02—Pretreatment
- C11B1/025—Pretreatment by enzymes or microorganisms, living or dead
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B1/00—Production of fats or fatty oils from raw materials
- C11B1/10—Production of fats or fatty oils from raw materials by extracting
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B1/00—Production of fats or fatty oils from raw materials
- C11B1/10—Production of fats or fatty oils from raw materials by extracting
- C11B1/108—Production of fats or fatty oils from raw materials by extracting after-treatment, e.g. of miscellae
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B3/00—Refining fats or fatty oils
- C11B3/001—Refining fats or fatty oils by a combination of two or more of the means hereafter
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B3/00—Refining fats or fatty oils
- C11B3/008—Refining fats or fatty oils by filtration, e.g. including ultra filtration, dialysis
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B3/00—Refining fats or fatty oils
- C11B3/02—Refining fats or fatty oils by chemical reaction
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B3/00—Refining fats or fatty oils
- C11B3/12—Refining fats or fatty oils by distillation
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B3/00—Refining fats or fatty oils
- C11B3/16—Refining fats or fatty oils by mechanical means
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
- C12N1/18—Baker's yeast; Brewer's yeast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Mechanical Engineering (AREA)
- Botany (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a high EPA/DPA type antarctic krill oil phospholipid oral liquid, belonging to the technical field of marine organisms. According to the invention, the antarctic krill powder is used as a raw material, and the modern biological separation technology, the biological enzymolysis technology and the mixed microbial fermentation technology are integrated, so that the extraction yield of the antarctic krill oil and the content of DHA, EPA and the like in the oral liquid are obviously improved, and the requirements of medical health on high fatigue resistance, cancer resistance and the like are met; the extraction rate of the antarctic krill oil is high, the content of functional accompanying substances such as phospholipid, astaxanthin, DHA, EPA and the like in the obtained antarctic krill oil phospholipid oral liquid is high, especially the content of DHA and EPA in the antarctic krill oil phospholipid oral liquid is obviously improved, and the method has a wide application and popularization prospect.
Description
Technical Field
The invention relates to a high-EPA/DPA type antarctic krill oil phospholipid oral liquid and a preparation method thereof, in particular to a high-EPA/DPA antarctic krill oil phospholipid oral liquid prepared by using antarctic krill powder as a raw material through synergistic fermentation of microorganisms, and belongs to the technical field of marine organisms.
Background
Antarctic continents are the only uncontaminated continents on the earth, and the world that has been praised as "clean and clear" is the last piece of "clean soil" on the earth. The ocean around the Antarctic continent is called a rich and clean "marine ranch", and the ocean is filled with living organisms, where there are seaweeds, corals, starfishes and sponges, and there are many small organisms called krill, which is food on which numerous fishes, seabirds, seals, penguins and whales in Antarctic continent live, and plays an important role in the south ocean food chain. Antarctic krill is the fourth largest resource in areas following grains, petroleum, coal. The storage amount of the antarctic krill is quite remarkable, and the nutritional value is extremely high. It is the highest protein-containing organism found today, with a protein content of more than fifty percent, and also contains a great abundance of amino acids and vitamin A essential for human tissues.
At present, Antarctic krill is mainly applied to medicine and food by Antarctic krill oil. Antarctic krill oil is extracted by a patent ultralow temperature extraction method, is natural health food given to human beings by nature, and has the effect that other foods cannot be replaced. The krill oil is clinically proved to have the advantages of ultra-strong blood fat reduction, blood sugar reduction, blood pressure reduction, nutrition passing through a blood brain barrier and activation of brain cells and nerves, and prevention and treatment of cerebrovascular diseases; simultaneously, preventing and treating coronary atherosclerosis and coronary heart disease, and preventing cardiovascular diseases such as myocardial infarction, stent, bypass, secondary recurrence and the like; in addition, the antarctic krill oil can also have multiple effects of resisting bacteria and diminishing inflammation, preventing the occurrence and development of cancers, delaying fatigue, regulating endocrine and the like.
Currently, regarding the preparation of antarctic krill oil in the prior art, mostly, an enzymatic hydrolysis or physical method is adopted for preparation, for example, patent 201810078300.X discloses a preparation method of antarctic krill oil, which takes antarctic krill powder as a raw material, and adopts a multi-stage grinding synergistic enzymatic hydrolysis method under a specific system condition to enrich crude components rich in lipid in antarctic krill, and then crude extracts are obtained through separation and drying processes; extracting the crude extract by using a mixed solvent of ethanol and ethyl acetate, and performing primary concentration, cooling, separation and secondary concentration on the extract to obtain high-quality euphausia superba oil; patent 201811290847.2 discloses a method for preparing antarctic krill oil with low unsaponifiable matter, which comprises the following steps: adding 75-99% ethanol solution into the crude antarctic krill oil, and uniformly stirring to obtain a mixed solution; adding cyclodextrin and/or cyclodextrin derivatives into the mixed solution, stirring and filtering to obtain filtrate; distilling the filtrate under reduced pressure to remove ethanol to obtain low unsaponifiable euphausia superba oil; patent 201811231007.9 discloses a high EPA/DHA type antarctic krill oil phospholipid oral liquid and a preparation method thereof, wherein the oral liquid comprises step S1: refining the antarctic krill oil to remove triglyceride, thereby obtaining an antarctic krill oil phospholipid solution; step S2: mixing the Antarctic krill oil phospholipid solution and the solvent according to a certain proportion, adjusting the pH value to be neutral, homogenizing under high pressure, and sterilizing to obtain the euphausia superba oil phospholipid gel. Compared with the prior art, the report that the high EPA/DHA antarctic krill oil phospholipid and the biological products thereof are prepared by a microbial fermentation synergistic enzymolysis method is not found in the prior art.
Disclosure of Invention
In order to overcome the defects of the prior art and meet the requirements of high-efficiency extraction and high-value utilization of antarctic krill oil, the application provides the high-EPA/DPA type antarctic krill oil phospholipid oral liquid, integrates the modern bioseparation technology, the biological enzymolysis technology and the mixed microbial fermentation technology, develops and develops the high-EPA/DPA antarctic krill oil phospholipid oral liquid, and meets the requirements of medical health on high fatigue resistance, cancer resistance and the like; the extraction rate of the antarctic krill oil is high, the content of functional accompanying substances such as phospholipid, astaxanthin, DHA, EPA and the like in the obtained antarctic krill oil phospholipid oral liquid is high, especially the content of DHA and EPA in the antarctic krill oil phospholipid oral liquid is obviously improved, and the method has a wide application and popularization prospect.
The invention realizes the technical effects through the following technical scheme:
a high EPA/DPA type antarctic krill oil phospholipid oral liquid mainly comprises the following steps:
(1) crushing: the method comprises the following steps of (1) crushing Antarctic krill powder serving as a raw material, and sieving the crushed Antarctic krill powder through a 100-mesh sieve;
(2) dissolving: adding 3 times of purified water into the antarctic krill powder obtained in the step (1), and uniformly stirring;
(3) and (3) sterilization: sterilizing the dissolved euphausia superba powder by using an autoclave, and cooling for later use;
(4) compound enzymolysis: adding a complex enzyme preparation with the mass ratio of 2% into the sterilized slurry, and stirring and performing enzymolysis for 30min at the temperature of 40-60 ℃;
(5) aerobic fermentation: adding a compound microbial agent with the mass ratio of 3% of the enzymolysis liquid into the enzymolysis liquid after enzymolysis, and carrying out aerobic fermentation for 16h at the temperature of 28-35 ℃;
(6) and (3) filtering: performing coarse filtration to remove fermentation thalli;
(7) enzyme deactivation: inactivating enzyme at 100 deg.C for 10 min;
(8) centrifuging: centrifuging at 10000r/min to remove insoluble components;
(9) and (3) drying: spray drying or freeze drying or drying under reduced pressure to water content of less than 10% to obtain crude extract;
(10) leaching of crude extract: adding an extracting agent with the volume ratio of 1: 1-20 times to the crude extract obtained in the step (10), and extracting at 10-60 ℃ for 2-5 hours to obtain a leaching solution; the extractant is a mixed solution of ethanol and ethyl acetate, wherein the volume fraction of the ethyl acetate is 20-40%;
(11) primary concentration, cooling, separation and secondary concentration: concentrating the leaching liquor obtained in the step (11) under reduced pressure until the oil content is more than 30% to obtain a first-stage concentrated solution; standing the primary concentrated solution for 1-2 hours at the temperature of 2-16 ℃, separating by filtering or centrifuging, and performing secondary vacuum concentration on the collected liquid until no solvent residue exists, thus obtaining the high-quality euphausia superba oil;
(12) removing triglyceride: adding a hydration solution which is 1-6 times of the mass content of phospholipid in the antarctic krill oil into the antarctic krill oil, heating while stirring for 30-120 min to 45-70 ℃, cooling, standing, and removing triglyceride through sedimentation separation or centrifugal separation to obtain the antarctic krill oil phospholipid solution; wherein the hydration solution contains 1.5 to 6 mass percent of citric acid;
(13) preparing oral liquid: adding 4-6 times of purified water into the Antarctic krill oil phospholipid solution, adding a flavoring agent with the mass ratio of the Antarctic krill oil phospholipid solution being 2-3%, adjusting the pH value to be neutral, and homogenizing under high pressure to obtain the oral liquid.
Preferably, the complex enzyme preparation in the step (4) is one or a mixture of more of protease, lipase and glucanase.
Preferably, the mass ratio of the protease, the lipase and the glucanase is 3:1: 1.
Preferably, the protease is one or more of pepsin, neutral protease, bromelain, trypsin, papain and flavourzyme.
Preferably, the lipase is one or a mixture of more of candida esterase, aspergillus esterase, pseudomonas esterase and rhizopus esterase.
Preferably, the lipase is a mixture of candida esterase and pseudomonas esterase in a mass ratio of 2: 1.
Preferably, the compound microbial agent in the step (5) is a mixed microbial agent of beer yeast, bacillus subtilis and bacillus megaterium, and the mass ratio of the compound microbial agent to the bacillus megaterium is 3:2: 1.
Preferably, the ventilation rate in the aerobic fermentation process in the step (5) is 0.2-0.3 m3/m3.min。
The preparation method of the beer yeast seed liquid comprises the following steps: under the aseptic operation condition, two rings of strains are picked from the inclined plane of the yeast YDP by using an inoculating ring, inoculated into a 500mL triangular flask containing 300mLPDA liquid culture medium, subjected to shaking culture at the temperature of between 28 and 32 ℃ and at the speed of 140r/min for 24 hours, and then inoculated into a seed tank for expanded culture according to the process to prepare the yeast seed liquid, wherein the effective viable count of the seed liquid is required to be more than or equal to 109cfu/mL。
The preparation method of the seed liquid of the bacillus subtilis and the bacillus megaterium comprises the following steps: under the aseptic condition, LB culture medium is adopted to culture for 24 hours under the condition of 28-32 ℃ to prepare liquid bacillus subtilis and bacillus megatherium seed liquid, and the effective viable count of the seed liquid is required to be more than or equal to 109cfu/mL。
The sweetener is one or more of trehalose, xylitol, sorbitol, mannitol, fructose syrup, and maltose.
The invention provides a high EPA/DPA type antarctic krill oil phospholipid oral liquid, which has the following remarkable advantages compared with the prior art:
(1) according to the application, the antarctic krill powder is used as a raw material, and the modern bioseparation technology, the biological enzymolysis technology and the mixed microbial fermentation technology are integrated, so that the extraction yield of the antarctic krill oil and the content of DHA, EPA and the like in the oral liquid are obviously improved; the complex enzyme preparation has obvious influence on the extraction yield and the active substance content of the antarctic krill oil, and especially has obvious influence on the improvement of the content of DHA, EPA and the like in the antarctic krill phospholipid oral liquid although the influence of glucanase on the extraction preparation of the antarctic krill oil is not obvious;
(2) this application utilizes aerobic bacteria (beer yeast, bacillus subtilis, bacillus megatherium) to ferment antarctic krill powder jointly and draws antarctic krill oil, and the synergistic effect between the make full use of microorganism promotes the content of DHA, EPA etc. in the antarctic krill phospholipid oral liquid, wherein: the beer yeast can generate various enzymes for degrading cell walls in the fermentation process, so that more antarctic krill oil is released from the cell walls, and the yeast is an enzyme capable of releasing combined state phenolic acid, so that the content of active substances in the antarctic krill oil is increased; the bacillus subtilis can kill pathogenic bacteria in fermentation liquor in the high-temperature fermentation process, has strong capacities of producing protease, protease and the like, and can degrade macromolecular starch and protein substances into microorganisms for utilization, so that the extraction yield of the euphausia superba oil is improved; the addition of the bacillus megaterium can obviously improve the content of DHA, EPA and the like in the antarctic krill oil;
(3) the method has simple production process, does not generate chemical change in the preparation process, does not change the chemical structures of DHA and EPA, ensures that the whole reaction process is environment-friendly and has low energy consumption, improves the content of DHA and EPA in the oral liquid, and is beneficial to industrial popularization.
Detailed Description
In the present application, the activation methods of Saccharomyces cerevisiae, Bacillus subtilis, and Bacillus megaterium are as follows:
(1) the preparation method of the beer yeast seed liquid comprises the following steps: under the aseptic operation condition, two rings of strains are picked from the inclined plane of the yeast YDP by using an inoculating ring, inoculated into a 500mL triangular flask containing 300mLPDA liquid culture medium, subjected to shaking culture at the temperature of between 28 and 32 ℃ and at the speed of 140r/min for 24 hours, and then inoculated into a seed tank for expanded culture according to the process to prepare the yeast seed liquid, wherein the effective viable count of the seed liquid is required to be more than or equal to 109cfu/mL；
(2) The preparation method of the seed liquid of the bacillus subtilis and the bacillus megaterium comprises the following steps: under the aseptic condition, LB culture medium is adopted to culture for 24 hours under the condition of 28-32 ℃ to prepare liquid bacillus subtilis and bacillus megatherium seed liquid, and the effective viable count of the seed liquid is required to be more than or equal to 109cfu/mL。
Example 1
A preparation method of high EPA/DPA type antarctic krill oil phospholipid oral liquid comprises the following steps:
(1) crushing: the method comprises the following steps of (1) crushing Antarctic krill powder serving as a raw material, and sieving the crushed Antarctic krill powder through a 100-mesh sieve;
(2) dissolving: adding 3 times of purified water into the antarctic krill powder obtained in the step (1), and uniformly stirring;
(3) and (3) sterilization: sterilizing the dissolved euphausia superba powder by using an autoclave, and cooling for later use;
(4) compound enzymolysis: adding a complex enzyme preparation with the mass ratio of 2% into the sterilized slurry, and stirring and performing enzymolysis for 30min at the temperature of 40-60 ℃; the compound enzyme preparation is a mixture of protease, lipase and glucanase, wherein the mass ratio of the protease, the lipase and the glucanase is 3:1: 1; the protease is a mixture of trypsin, papain and flavourzyme in equal mass; the lipase is a mixture of candida esterase and pseudomonas esterase, and the mass ratio of the lipase to the pseudomonas esterase is 2: 1;
(5) aerobic fermentation: adding a compound microbial agent with the mass ratio of 3% of the enzymolysis liquid into the enzymolysis liquid after enzymolysis, and carrying out aerobic fermentation for 8h at the temperature of 28-35 ℃; the composite microbial agent is a mixed microbial agent of beer yeast, bacillus subtilis and bacillus megaterium, and the mass ratio of the composite microbial agent to the bacillus megaterium is 3:2: 1;
(6) and (3) filtering: performing coarse filtration to remove fermentation thalli;
(7) enzyme deactivation: inactivating enzyme at 100 deg.C for 10 min;
(8) centrifuging: centrifuging at 10000r/min to remove insoluble components;
(9) and (3) drying: spray drying or freeze drying or drying under reduced pressure to water content of less than 10% to obtain crude extract;
(10) leaching of crude extract: adding an extracting agent with the volume ratio of 1: 1-20 times to the crude extract obtained in the step (10), and extracting at 10-60 ℃ for 2-5 hours to obtain a leaching solution; the extractant is a mixed solution of ethanol and ethyl acetate, wherein the volume fraction of the ethyl acetate is 20-40%;
(11) primary concentration, cooling, separation and secondary concentration: concentrating the leaching liquor obtained in the step (11) under reduced pressure until the oil content is more than 30% to obtain a first-stage concentrated solution; standing the primary concentrated solution for 1-2 hours at the temperature of 2-16 ℃, separating by filtering or centrifuging, and performing secondary vacuum concentration on the collected liquid until no solvent residue exists, thus obtaining the high-quality euphausia superba oil;
(12) removing triglyceride: adding a hydration solution which is 1-6 times of the mass content of phospholipid in the antarctic krill oil into the antarctic krill oil, heating while stirring for 30-120 min to 45-70 ℃, cooling, standing, and removing triglyceride through sedimentation separation or centrifugal separation to obtain the antarctic krill oil phospholipid solution; wherein the hydration solution contains 1.5 to 6 mass percent of citric acid;
(13) preparing oral liquid: adding 4-6 times of purified water into the Antarctic krill oil phospholipid solution, adding a flavoring agent with the mass ratio of the Antarctic krill oil phospholipid solution being 2-3%, adjusting the pH value to be neutral, and homogenizing under high pressure to obtain the oral liquid.
Example 2
A preparation method of high EPA/DPA type antarctic krill oil phospholipid oral liquid comprises the following steps:
(1) crushing: the method comprises the following steps of (1) crushing Antarctic krill powder serving as a raw material, and sieving the crushed Antarctic krill powder through a 100-mesh sieve;
(2) dissolving: adding 3 times of purified water into the antarctic krill powder obtained in the step (1), and uniformly stirring;
(3) and (3) sterilization: sterilizing the dissolved euphausia superba powder by using an autoclave, and cooling for later use;
(4) compound enzymolysis: adding a complex enzyme preparation with the mass ratio of 2% into the sterilized slurry, and stirring and performing enzymolysis for 30min at the temperature of 40-60 ℃; the compound enzyme preparation is protease; the protease is a mixture of trypsin, papain and flavourzyme in equal mass;
(5) aerobic fermentation: adding a compound microbial agent with the mass ratio of 3% of the enzymolysis liquid into the enzymolysis liquid after enzymolysis, and carrying out aerobic fermentation for 8h at the temperature of 28-35 ℃; the composite microbial agent is a mixed microbial agent of beer yeast, bacillus subtilis and bacillus megaterium, and the mass ratio of the composite microbial agent to the bacillus megaterium is 3:2: 1;
(6) and (3) filtering: performing coarse filtration to remove fermentation thalli;
(7) enzyme deactivation: inactivating enzyme at 100 deg.C for 10 min;
(8) centrifuging: centrifuging at 10000r/min to remove insoluble components;
(9) and (3) drying: spray drying or freeze drying or drying under reduced pressure to water content of less than 10% to obtain crude extract;
(10) leaching of crude extract: adding an extracting agent with the volume ratio of 1: 1-20 times to the crude extract obtained in the step (10), and extracting at 10-60 ℃ for 2-5 hours to obtain a leaching solution; the extractant is a mixed solution of ethanol and ethyl acetate, wherein the volume fraction of the ethyl acetate is 20-40%;
(11) primary concentration, cooling, separation and secondary concentration: concentrating the leaching liquor obtained in the step (11) under reduced pressure until the oil content is more than 30% to obtain a first-stage concentrated solution; standing the primary concentrated solution for 1-2 hours at the temperature of 2-16 ℃, separating by filtering or centrifuging, and performing secondary vacuum concentration on the collected liquid until no solvent residue exists, thus obtaining the high-quality euphausia superba oil;
(12) removing triglyceride: adding a hydration solution which is 1-6 times of the mass content of phospholipid in the antarctic krill oil into the antarctic krill oil, heating while stirring for 30-120 min to 45-70 ℃, cooling, standing, and removing triglyceride through sedimentation separation or centrifugal separation to obtain the antarctic krill oil phospholipid solution; wherein the hydration solution contains 1.5 to 6 mass percent of citric acid;
(13) preparing oral liquid: adding 4-6 times of purified water into the Antarctic krill oil phospholipid solution, adding a flavoring agent with the mass ratio of the Antarctic krill oil phospholipid solution being 2-3%, adjusting the pH value to be neutral, and homogenizing under high pressure to obtain the oral liquid.
Example 3
A preparation method of high EPA/DPA type antarctic krill oil phospholipid oral liquid comprises the following steps:
(1) crushing: the method comprises the following steps of (1) crushing Antarctic krill powder serving as a raw material, and sieving the crushed Antarctic krill powder through a 100-mesh sieve;
(2) dissolving: adding 3 times of purified water into the antarctic krill powder obtained in the step (1), and uniformly stirring;
(3) and (3) sterilization: sterilizing the dissolved euphausia superba powder by using an autoclave, and cooling for later use;
(4) compound enzymolysis: adding a complex enzyme preparation with the mass ratio of 2% into the sterilized slurry, and stirring and performing enzymolysis for 30min at the temperature of 40-60 ℃; the compound enzyme preparation is lipase; the lipase is a mixture of candida esterase and pseudomonas esterase, and the mass ratio of the lipase to the pseudomonas esterase is 2: 1;
(5) aerobic fermentation: adding a compound microbial agent with the mass ratio of 3% of the enzymolysis liquid into the enzymolysis liquid after enzymolysis, and carrying out aerobic fermentation for 8h at the temperature of 28-35 ℃; the composite microbial agent is a mixed microbial agent of beer yeast, bacillus subtilis and bacillus megaterium, and the mass ratio of the composite microbial agent to the bacillus megaterium is 3:2: 1;
(6) and (3) filtering: performing coarse filtration to remove fermentation thalli;
(7) enzyme deactivation: inactivating enzyme at 100 deg.C for 10 min;
(8) centrifuging: centrifuging at 10000r/min to remove insoluble components;
(9) and (3) drying: spray drying or freeze drying or drying under reduced pressure to water content of less than 10% to obtain crude extract;
(10) leaching of crude extract: adding an extracting agent with the volume ratio of 1: 1-20 times to the crude extract obtained in the step (10), and extracting at 10-60 ℃ for 2-5 hours to obtain a leaching solution; the extractant is a mixed solution of ethanol and ethyl acetate, wherein the volume fraction of the ethyl acetate is 20-40%;
(11) primary concentration, cooling, separation and secondary concentration: concentrating the leaching liquor obtained in the step (11) under reduced pressure until the oil content is more than 30% to obtain a first-stage concentrated solution; standing the primary concentrated solution for 1-2 hours at the temperature of 2-16 ℃, separating by filtering or centrifuging, and performing secondary vacuum concentration on the collected liquid until no solvent residue exists, thus obtaining the high-quality euphausia superba oil;
(12) removing triglyceride: adding a hydration solution which is 1-6 times of the mass content of phospholipid in the antarctic krill oil into the antarctic krill oil, heating while stirring for 30-120 min to 45-70 ℃, cooling, standing, and removing triglyceride through sedimentation separation or centrifugal separation to obtain the antarctic krill oil phospholipid solution; wherein the hydration solution contains 1.5 to 6 mass percent of citric acid;
(13) preparing oral liquid: adding 4-6 times of purified water into the Antarctic krill oil phospholipid solution, adding a flavoring agent with the mass ratio of the Antarctic krill oil phospholipid solution being 2-3%, adjusting the pH value to be neutral, and homogenizing under high pressure to obtain the oral liquid.
Example 4
A preparation method of high EPA/DPA type antarctic krill oil phospholipid oral liquid comprises the following steps:
(1) crushing: the method comprises the following steps of (1) crushing Antarctic krill powder serving as a raw material, and sieving the crushed Antarctic krill powder through a 100-mesh sieve;
(2) dissolving: adding 3 times of purified water into the antarctic krill powder obtained in the step (1), and uniformly stirring;
(3) and (3) sterilization: sterilizing the dissolved euphausia superba powder by using an autoclave, and cooling for later use;
(4) compound enzymolysis: adding a complex enzyme preparation with the mass ratio of 2% into the sterilized slurry, and stirring and performing enzymolysis for 30min at the temperature of 40-60 ℃; the compound enzyme preparation is glucanase;
(5) aerobic fermentation: adding a compound microbial agent with the mass ratio of 3% of the enzymolysis liquid into the enzymolysis liquid after enzymolysis, and carrying out aerobic fermentation for 8h at the temperature of 28-35 ℃; the composite microbial agent is a mixed microbial agent of beer yeast, bacillus subtilis and bacillus megaterium, and the mass ratio of the composite microbial agent to the bacillus megaterium is 3:2: 1;
(6) and (3) filtering: performing coarse filtration to remove fermentation thalli;
(7) enzyme deactivation: inactivating enzyme at 100 deg.C for 10 min;
(8) centrifuging: centrifuging at 10000r/min to remove insoluble components;
(9) and (3) drying: spray drying or freeze drying or drying under reduced pressure to water content of less than 10% to obtain crude extract;
(10) leaching of crude extract: adding an extracting agent with the volume ratio of 1: 1-20 times to the crude extract obtained in the step (10), and extracting at 10-60 ℃ for 2-5 hours to obtain a leaching solution; the extractant is a mixed solution of ethanol and ethyl acetate, wherein the volume fraction of the ethyl acetate is 20-40%;
(11) primary concentration, cooling, separation and secondary concentration: concentrating the leaching liquor obtained in the step (11) under reduced pressure until the oil content is more than 30% to obtain a first-stage concentrated solution; standing the primary concentrated solution for 1-2 hours at the temperature of 2-16 ℃, separating by filtering or centrifuging, and performing secondary vacuum concentration on the collected liquid until no solvent residue exists, thus obtaining the high-quality euphausia superba oil;
(12) removing triglyceride: adding a hydration solution which is 1-6 times of the mass content of phospholipid in the antarctic krill oil into the antarctic krill oil, heating while stirring for 30-120 min to 45-70 ℃, cooling, standing, and removing triglyceride through sedimentation separation or centrifugal separation to obtain the antarctic krill oil phospholipid solution; wherein the hydration solution contains 1.5 to 6 mass percent of citric acid;
(13) preparing oral liquid: adding 4-6 times of purified water into the Antarctic krill oil phospholipid solution, adding a flavoring agent with the mass ratio of the Antarctic krill oil phospholipid solution being 2-3%, adjusting the pH value to be neutral, and homogenizing under high pressure to obtain the oral liquid.
Example 5
A preparation method of high EPA/DPA type antarctic krill oil phospholipid oral liquid comprises the following steps:
(1) crushing: the method comprises the following steps of (1) crushing Antarctic krill powder serving as a raw material, and sieving the crushed Antarctic krill powder through a 100-mesh sieve;
(2) dissolving: adding 3 times of purified water into the antarctic krill powder obtained in the step (1), and uniformly stirring;
(3) and (3) sterilization: sterilizing the dissolved euphausia superba powder by using an autoclave, and cooling for later use;
(4) compound enzymolysis: adding a complex enzyme preparation with the mass ratio of 2% into the sterilized slurry, and stirring and performing enzymolysis for 30min at the temperature of 40-60 ℃; the compound enzyme preparation is a mixture of protease and lipase, wherein the mass ratio of the protease to the lipase is 3: 1; the protease is a mixture of trypsin, papain and flavourzyme in equal mass; the lipase is a mixture of candida esterase and pseudomonas esterase, and the mass ratio of the lipase to the pseudomonas esterase is 2: 1;
(5) aerobic fermentation: adding a compound microbial agent with the mass ratio of 3% of the enzymolysis liquid into the enzymolysis liquid after enzymolysis, and carrying out aerobic fermentation for 8h at the temperature of 28-35 ℃; the composite microbial agent is a mixed microbial agent of beer yeast, bacillus subtilis and bacillus megaterium, and the mass ratio of the composite microbial agent to the bacillus megaterium is 3:2: 1;
(6) and (3) filtering: performing coarse filtration to remove fermentation thalli;
(7) enzyme deactivation: inactivating enzyme at 100 deg.C for 10 min;
(8) centrifuging: centrifuging at 10000r/min to remove insoluble components;
(9) and (3) drying: spray drying or freeze drying or drying under reduced pressure to water content of less than 10% to obtain crude extract;
(10) leaching of crude extract: adding an extracting agent with the volume ratio of 1: 1-20 times to the crude extract obtained in the step (10), and extracting at 10-60 ℃ for 2-5 hours to obtain a leaching solution; the extractant is a mixed solution of ethanol and ethyl acetate, wherein the volume fraction of the ethyl acetate is 20-40%;
(11) primary concentration, cooling, separation and secondary concentration: concentrating the leaching liquor obtained in the step (11) under reduced pressure until the oil content is more than 30% to obtain a first-stage concentrated solution; standing the primary concentrated solution for 1-2 hours at the temperature of 2-16 ℃, separating by filtering or centrifuging, and performing secondary vacuum concentration on the collected liquid until no solvent residue exists, thus obtaining the high-quality euphausia superba oil;
(12) removing triglyceride: adding a hydration solution which is 1-6 times of the mass content of phospholipid in the antarctic krill oil into the antarctic krill oil, heating while stirring for 30-120 min to 45-70 ℃, cooling, standing, and removing triglyceride through sedimentation separation or centrifugal separation to obtain the antarctic krill oil phospholipid solution; wherein the hydration solution contains 1.5 to 6 mass percent of citric acid;
(13) preparing oral liquid: adding 4-6 times of purified water into the Antarctic krill oil phospholipid solution, adding a flavoring agent with the mass ratio of the Antarctic krill oil phospholipid solution being 2-3%, adjusting the pH value to be neutral, and homogenizing under high pressure to obtain the oral liquid.
Example 6
A preparation method of high EPA/DPA type antarctic krill oil phospholipid oral liquid comprises the following steps:
(1) crushing: the method comprises the following steps of (1) crushing Antarctic krill powder serving as a raw material, and sieving the crushed Antarctic krill powder through a 100-mesh sieve;
(2) dissolving: adding 3 times of purified water into the antarctic krill powder obtained in the step (1), and uniformly stirring;
(3) and (3) sterilization: sterilizing the dissolved euphausia superba powder by using an autoclave, and cooling for later use;
(4) compound enzymolysis: adding a complex enzyme preparation with the mass ratio of 2% into the sterilized slurry, and stirring and performing enzymolysis for 30min at the temperature of 40-60 ℃; the compound enzyme preparation is a mixture of protease and glucanase, wherein the mass ratio of the protease to the glucanase is 3: 1; the protease is a mixture of trypsin, papain and flavourzyme in equal mass;
(5) aerobic fermentation: adding a compound microbial agent with the mass ratio of 3% of the enzymolysis liquid into the enzymolysis liquid after enzymolysis, and carrying out aerobic fermentation for 8h at the temperature of 28-35 ℃; the composite microbial agent is a mixed microbial agent of beer yeast, bacillus subtilis and bacillus megaterium, and the mass ratio of the composite microbial agent to the bacillus megaterium is 3:2: 1;
(6) and (3) filtering: performing coarse filtration to remove fermentation thalli;
(7) enzyme deactivation: inactivating enzyme at 100 deg.C for 10 min;
(8) centrifuging: centrifuging at 10000r/min to remove insoluble components;
(9) and (3) drying: spray drying or freeze drying or drying under reduced pressure to water content of less than 10% to obtain crude extract;
(10) leaching of crude extract: adding an extracting agent with the volume ratio of 1: 1-20 times to the crude extract obtained in the step (10), and extracting at 10-60 ℃ for 2-5 hours to obtain a leaching solution; the extractant is a mixed solution of ethanol and ethyl acetate, wherein the volume fraction of the ethyl acetate is 20-40%;
(11) primary concentration, cooling, separation and secondary concentration: concentrating the leaching liquor obtained in the step (11) under reduced pressure until the oil content is more than 30% to obtain a first-stage concentrated solution; standing the primary concentrated solution for 1-2 hours at the temperature of 2-16 ℃, separating by filtering or centrifuging, and performing secondary vacuum concentration on the collected liquid until no solvent residue exists, thus obtaining the high-quality euphausia superba oil;
(12) removing triglyceride: adding a hydration solution which is 1-6 times of the mass content of phospholipid in the antarctic krill oil into the antarctic krill oil, heating while stirring for 30-120 min to 45-70 ℃, cooling, standing, and removing triglyceride through sedimentation separation or centrifugal separation to obtain the antarctic krill oil phospholipid solution; wherein the hydration solution contains 1.5 to 6 mass percent of citric acid;
(13) preparing oral liquid: adding 4-6 times of purified water into the Antarctic krill oil phospholipid solution, adding a flavoring agent with the mass ratio of the Antarctic krill oil phospholipid solution being 2-3%, adjusting the pH value to be neutral, and homogenizing under high pressure to obtain the oral liquid.
Example 7
A preparation method of high EPA/DPA type antarctic krill oil phospholipid oral liquid comprises the following steps:
(1) crushing: the method comprises the following steps of (1) crushing Antarctic krill powder serving as a raw material, and sieving the crushed Antarctic krill powder through a 100-mesh sieve;
(2) dissolving: adding 3 times of purified water into the antarctic krill powder obtained in the step (1), and uniformly stirring;
(3) and (3) sterilization: sterilizing the dissolved euphausia superba powder by using an autoclave, and cooling for later use;
(4) compound enzymolysis: adding a complex enzyme preparation with the mass ratio of 2% into the sterilized slurry, and stirring and performing enzymolysis for 30min at the temperature of 40-60 ℃; the compound enzyme preparation is a mixture of protease, lipase and glucanase, wherein the mass ratio of the protease, the lipase and the glucanase is 3:1: 1; the protease is a mixture of trypsin, papain and flavourzyme in equal mass; the lipase is candida esterase;
(5) aerobic fermentation: adding a compound microbial agent with the mass ratio of 3% of the enzymolysis liquid into the enzymolysis liquid after enzymolysis, and carrying out aerobic fermentation for 8h at the temperature of 28-35 ℃; the composite microbial agent is a mixed microbial agent of beer yeast, bacillus subtilis and bacillus megaterium, and the mass ratio of the composite microbial agent to the bacillus megaterium is 3:2: 1;
(6) and (3) filtering: performing coarse filtration to remove fermentation thalli;
(7) enzyme deactivation: inactivating enzyme at 100 deg.C for 10 min;
(8) centrifuging: centrifuging at 10000r/min to remove insoluble components;
(9) and (3) drying: spray drying or freeze drying or drying under reduced pressure to water content of less than 10% to obtain crude extract;
(10) leaching of crude extract: adding an extracting agent with the volume ratio of 1: 1-20 times to the crude extract obtained in the step (10), and extracting at 10-60 ℃ for 2-5 hours to obtain a leaching solution; the extractant is a mixed solution of ethanol and ethyl acetate, wherein the volume fraction of the ethyl acetate is 20-40%;
(11) primary concentration, cooling, separation and secondary concentration: concentrating the leaching liquor obtained in the step (11) under reduced pressure until the oil content is more than 30% to obtain a first-stage concentrated solution; standing the primary concentrated solution for 1-2 hours at the temperature of 2-16 ℃, separating by filtering or centrifuging, and performing secondary vacuum concentration on the collected liquid until no solvent residue exists, thus obtaining the high-quality euphausia superba oil;
(12) removing triglyceride: adding a hydration solution which is 1-6 times of the mass content of phospholipid in the antarctic krill oil into the antarctic krill oil, heating while stirring for 30-120 min to 45-70 ℃, cooling, standing, and removing triglyceride through sedimentation separation or centrifugal separation to obtain the antarctic krill oil phospholipid solution; wherein the hydration solution contains 1.5 to 6 mass percent of citric acid;
(13) preparing oral liquid: adding 4-6 times of purified water into the Antarctic krill oil phospholipid solution, adding a flavoring agent with the mass ratio of the Antarctic krill oil phospholipid solution being 2-3%, adjusting the pH value to be neutral, and homogenizing under high pressure to obtain the oral liquid.
Example 8
A preparation method of high EPA/DPA type antarctic krill oil phospholipid oral liquid comprises the following steps:
(1) crushing: the method comprises the following steps of (1) crushing Antarctic krill powder serving as a raw material, and sieving the crushed Antarctic krill powder through a 100-mesh sieve;
(2) dissolving: adding 3 times of purified water into the antarctic krill powder obtained in the step (1), and uniformly stirring;
(3) and (3) sterilization: sterilizing the dissolved euphausia superba powder by using an autoclave, and cooling for later use;
(4) compound enzymolysis: adding a complex enzyme preparation with the mass ratio of 2% into the sterilized slurry, and stirring and performing enzymolysis for 30min at the temperature of 40-60 ℃; the compound enzyme preparation is a mixture of protease, lipase and glucanase, wherein the mass ratio of the protease, the lipase and the glucanase is 3:1: 1; the protease is a mixture of trypsin, papain and flavourzyme in equal mass; the lipase is pseudomonas esterase;
(5) aerobic fermentation: adding a compound microbial agent with the mass ratio of 3% of the enzymolysis liquid into the enzymolysis liquid after enzymolysis, and carrying out aerobic fermentation for 8h at the temperature of 28-35 ℃; the composite microbial agent is a mixed microbial agent of beer yeast, bacillus subtilis and bacillus megaterium, and the mass ratio of the composite microbial agent to the bacillus megaterium is 3:2: 1;
(6) and (3) filtering: performing coarse filtration to remove fermentation thalli;
(7) enzyme deactivation: inactivating enzyme at 100 deg.C for 10 min;
(8) centrifuging: centrifuging at 10000r/min to remove insoluble components;
(9) and (3) drying: spray drying or freeze drying or drying under reduced pressure to water content of less than 10% to obtain crude extract;
(10) leaching of crude extract: adding an extracting agent with the volume ratio of 1: 1-20 times to the crude extract obtained in the step (10), and extracting at 10-60 ℃ for 2-5 hours to obtain a leaching solution; the extractant is a mixed solution of ethanol and ethyl acetate, wherein the volume fraction of the ethyl acetate is 20-40%;
(11) primary concentration, cooling, separation and secondary concentration: concentrating the leaching liquor obtained in the step (11) under reduced pressure until the oil content is more than 30% to obtain a first-stage concentrated solution; standing the primary concentrated solution for 1-2 hours at the temperature of 2-16 ℃, separating by filtering or centrifuging, and performing secondary vacuum concentration on the collected liquid until no solvent residue exists, thus obtaining the high-quality euphausia superba oil;
(12) removing triglyceride: adding a hydration solution which is 1-6 times of the mass content of phospholipid in the antarctic krill oil into the antarctic krill oil, heating while stirring for 30-120 min to 45-70 ℃, cooling, standing, and removing triglyceride through sedimentation separation or centrifugal separation to obtain the antarctic krill oil phospholipid solution; wherein the hydration solution contains 1.5 to 6 mass percent of citric acid;
(13) preparing oral liquid: adding 4-6 times of purified water into the Antarctic krill oil phospholipid solution, adding a flavoring agent with the mass ratio of the Antarctic krill oil phospholipid solution being 2-3%, adjusting the pH value to be neutral, and homogenizing under high pressure to obtain the oral liquid.
Example 9
A preparation method of high EPA/DPA type antarctic krill oil phospholipid oral liquid comprises the following steps:
(1) crushing: the method comprises the following steps of (1) crushing Antarctic krill powder serving as a raw material, and sieving the crushed Antarctic krill powder through a 100-mesh sieve;
(2) dissolving: adding 3 times of purified water into the antarctic krill powder obtained in the step (1), and uniformly stirring;
(3) and (3) sterilization: sterilizing the dissolved euphausia superba powder by using an autoclave, and cooling for later use;
(4) compound enzymolysis: adding a complex enzyme preparation with the mass ratio of 2% into the sterilized slurry, and stirring and performing enzymolysis for 30min at the temperature of 40-60 ℃; the compound enzyme preparation is a mixture of protease, lipase and glucanase, wherein the mass ratio of the protease, the lipase and the glucanase is 3:1: 1; the protease is a mixture of trypsin, papain and flavourzyme in equal mass; the lipase is a mixture of candida esterase and pseudomonas esterase, and the mass ratio of the lipase to the pseudomonas esterase is 1: 2;
(5) aerobic fermentation: adding a compound microbial agent with the mass ratio of 3% of the enzymolysis liquid into the enzymolysis liquid after enzymolysis, and carrying out aerobic fermentation for 8h at the temperature of 28-35 ℃; the composite microbial agent is a mixed microbial agent of beer yeast, bacillus subtilis and bacillus megaterium, and the mass ratio of the composite microbial agent to the bacillus megaterium is 3:2: 1;
(6) and (3) filtering: performing coarse filtration to remove fermentation thalli;
(7) enzyme deactivation: inactivating enzyme at 100 deg.C for 10 min;
(8) centrifuging: centrifuging at 10000r/min to remove insoluble components;
(9) and (3) drying: spray drying or freeze drying or drying under reduced pressure to water content of less than 10% to obtain crude extract;
(10) leaching of crude extract: adding an extracting agent with the volume ratio of 1: 1-20 times to the crude extract obtained in the step (10), and extracting at 10-60 ℃ for 2-5 hours to obtain a leaching solution; the extractant is a mixed solution of ethanol and ethyl acetate, wherein the volume fraction of the ethyl acetate is 20-40%;
(11) primary concentration, cooling, separation and secondary concentration: concentrating the leaching liquor obtained in the step (11) under reduced pressure until the oil content is more than 30% to obtain a first-stage concentrated solution; standing the primary concentrated solution for 1-2 hours at the temperature of 2-16 ℃, separating by filtering or centrifuging, and performing secondary vacuum concentration on the collected liquid until no solvent residue exists, thus obtaining the high-quality euphausia superba oil;
(12) removing triglyceride: adding a hydration solution which is 1-6 times of the mass content of phospholipid in the antarctic krill oil into the antarctic krill oil, heating while stirring for 30-120 min to 45-70 ℃, cooling, standing, and removing triglyceride through sedimentation separation or centrifugal separation to obtain the antarctic krill oil phospholipid solution; wherein the hydration solution contains 1.5 to 6 mass percent of citric acid;
(13) preparing oral liquid: adding 4-6 times of purified water into the Antarctic krill oil phospholipid solution, adding a flavoring agent with the mass ratio of the Antarctic krill oil phospholipid solution being 2-3%, adjusting the pH value to be neutral, and homogenizing under high pressure to obtain the oral liquid.
Comparative example 1
A preparation method of high EPA/DPA type antarctic krill oil phospholipid oral liquid comprises the following steps:
(1) crushing: the method comprises the following steps of (1) crushing Antarctic krill powder serving as a raw material, and sieving the crushed Antarctic krill powder through a 100-mesh sieve;
(2) dissolving: adding 3 times of purified water into the antarctic krill powder obtained in the step (1), and uniformly stirring;
(3) and (3) sterilization: sterilizing the dissolved euphausia superba powder by using an autoclave, and cooling for later use;
(4) compound enzymolysis: stirring and performing enzymolysis on the sterilized slurry for 30min at the temperature of 40-60 ℃;
(5) aerobic fermentation: adding a compound microbial agent with the mass ratio of 3% of the enzymolysis liquid into the enzymolysis liquid after enzymolysis, and carrying out aerobic fermentation for 8h at the temperature of 28-35 ℃; the composite microbial agent is a mixed microbial agent of beer yeast, bacillus subtilis and bacillus megaterium, and the mass ratio of the composite microbial agent to the bacillus megaterium is 3:2: 1;
(6) and (3) filtering: performing coarse filtration to remove fermentation thalli;
(7) enzyme deactivation: inactivating enzyme at 100 deg.C for 10 min;
(8) centrifuging: centrifuging at 10000r/min to remove insoluble components;
(9) and (3) drying: spray drying or freeze drying or drying under reduced pressure to water content of less than 10% to obtain crude extract;
(10) leaching of crude extract: adding an extracting agent with the volume ratio of 1: 1-20 times to the crude extract obtained in the step (10), and extracting at 10-60 ℃ for 2-5 hours to obtain a leaching solution; the extractant is a mixed solution of ethanol and ethyl acetate, wherein the volume fraction of the ethyl acetate is 20-40%;
(11) primary concentration, cooling, separation and secondary concentration: concentrating the leaching liquor obtained in the step (11) under reduced pressure until the oil content is more than 30% to obtain a first-stage concentrated solution; standing the primary concentrated solution for 1-2 hours at the temperature of 2-16 ℃, separating by filtering or centrifuging, and performing secondary vacuum concentration on the collected liquid until no solvent residue exists, thus obtaining the high-quality euphausia superba oil;
(12) removing triglyceride: adding a hydration solution which is 1-6 times of the mass content of phospholipid in the antarctic krill oil into the antarctic krill oil, heating while stirring for 30-120 min to 45-70 ℃, cooling, standing, and removing triglyceride through sedimentation separation or centrifugal separation to obtain the antarctic krill oil phospholipid solution; wherein the hydration solution contains 1.5 to 6 mass percent of citric acid;
(13) preparing oral liquid: adding 4-6 times of purified water into the Antarctic krill oil phospholipid solution, adding a flavoring agent with the mass ratio of the Antarctic krill oil phospholipid solution being 2-3%, adjusting the pH value to be neutral, and homogenizing under high pressure to obtain the oral liquid.
Comparative example 2
A high EPA/DPA type antarctic krill oil phospholipid oral liquid mainly comprises the following steps:
(1) crushing: the method comprises the following steps of (1) crushing Antarctic krill powder serving as a raw material, and sieving the crushed Antarctic krill powder through a 100-mesh sieve;
(2) dissolving: adding 3 times of purified water into the antarctic krill powder obtained in the step (1), and uniformly stirring;
(3) and (3) sterilization: sterilizing the dissolved euphausia superba powder by using an autoclave, and cooling for later use;
(4) compound enzymolysis: adding a complex enzyme preparation with the mass ratio of 2% into the sterilized slurry, and stirring and performing enzymolysis for 30min at the temperature of 40-60 ℃; the compound enzyme preparation is a mixture of protease, lipase and glucanase, wherein the mass ratio of the protease, the lipase and the glucanase is 3:1: 1; the protease is a mixture of trypsin, papain and flavourzyme in equal mass; the lipase is a mixture of candida esterase and pseudomonas esterase, and the mass ratio of the lipase to the pseudomonas esterase is 2: 1;
(6) enzyme deactivation: inactivating enzyme at 100 deg.C for 10 min;
(7) centrifuging: centrifuging at 10000r/min to remove insoluble components;
(8) and (3) drying: spray drying or freeze drying or drying under reduced pressure to water content of less than 10% to obtain crude extract;
(9) leaching of crude extract: adding an extracting agent with the volume ratio of 1: 1-20 times to the crude extract obtained in the step (10), and extracting at 10-60 ℃ for 2-5 hours to obtain a leaching solution; the extractant is a mixed solution of ethanol and ethyl acetate, wherein the volume fraction of the ethyl acetate is 20-40%;
(10) primary concentration, cooling, separation and secondary concentration: concentrating the leaching liquor obtained in the step (11) under reduced pressure until the oil content is more than 30% to obtain a first-stage concentrated solution; standing the primary concentrated solution for 1-2 hours at the temperature of 2-16 ℃, separating by filtering or centrifuging, and performing secondary vacuum concentration on the collected liquid until no solvent residue exists, thus obtaining the high-quality euphausia superba oil;
(11) removing triglyceride: adding a hydration solution which is 1-6 times of the mass content of phospholipid in the antarctic krill oil into the antarctic krill oil, heating while stirring for 30-120 min to 45-70 ℃, cooling, standing, and removing triglyceride through sedimentation separation or centrifugal separation to obtain the antarctic krill oil phospholipid solution; wherein the hydration solution contains 1.5 to 6 mass percent of citric acid;
(13) preparing oral liquid: adding 4-6 times of purified water into the Antarctic krill oil phospholipid solution, adding a flavoring agent with the mass ratio of the Antarctic krill oil phospholipid solution being 2-3%, adjusting the pH value to be neutral, and homogenizing under high pressure to obtain the oral liquid.
Example 10 evaluation tables for Euphausia superba oil of different test groups
TABLE 1 evaluation table of Euphausia superba oil phospholipid oral liquid for different test groups
The above experiment results show that the implementation of the invention has better phospholipid extraction rate, and the content of phospholipid, DHA and EPA in the Antarctic krill oil is higher, and example 1 is the best example of the invention. In addition, the test results show that the enzymolysis effect of the compound enzyme preparation and the fermentation effect of the compound microorganisms have significant influence on the content of phospholipid, DHA and EPA in the antarctic krill oil phospholipid oral liquid.
The above embodiments are only used for illustrating the technical solution of the present invention, and not for limiting the same; although the invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof; such modifications and substitutions do not depart from the spirit and scope of the present invention as set forth in the appended claims.
Claims (10)
1. A high EPA/DPA type antarctic krill oil phospholipid oral liquid is characterized in that the preparation method mainly comprises the following steps:
(1) crushing: the method comprises the following steps of (1) crushing Antarctic krill powder serving as a raw material, and sieving the crushed Antarctic krill powder through a 100-mesh sieve;
(2) dissolving: adding 3 times of purified water into the antarctic krill powder obtained in the step (1), and uniformly stirring;
(3) and (3) sterilization: sterilizing the dissolved euphausia superba powder by using an autoclave, and cooling for later use;
(4) compound enzymolysis: adding a complex enzyme preparation with the mass ratio of 2% into the sterilized slurry, and stirring and performing enzymolysis for 30min at the temperature of 40-60 ℃;
(5) aerobic fermentation: adding a compound microbial agent with the mass ratio of 3% of the enzymolysis liquid into the enzymolysis liquid after enzymolysis, and carrying out aerobic fermentation for 16h at the temperature of 28-35 ℃;
(6) and (3) filtering: performing coarse filtration to remove fermentation thalli;
(7) enzyme deactivation: inactivating enzyme at 100 deg.C for 10 min;
(8) centrifuging: centrifuging at 10000r/min to remove insoluble components;
(9) and (3) drying: spray drying or freeze drying or drying under reduced pressure to water content of less than 10% to obtain crude extract;
(10) leaching of crude extract: adding an extracting agent with the volume ratio of 1: 1-20 times to the crude extract obtained in the step (10), and extracting at 10-60 ℃ for 2-5 hours to obtain a leaching solution; the extractant is a mixed solution of ethanol and ethyl acetate, wherein the volume fraction of the ethyl acetate is 20-40%;
(11) primary concentration, cooling, separation and secondary concentration: concentrating the leaching liquor obtained in the step (11) under reduced pressure until the oil content is more than 30% to obtain a first-stage concentrated solution; standing the primary concentrated solution for 1-2 hours at the temperature of 2-16 ℃, separating by filtering or centrifuging, and performing secondary vacuum concentration on the collected liquid until no solvent residue exists, thus obtaining the high-quality euphausia superba oil;
(12) removing triglyceride: adding a hydration solution which is 1-6 times of the mass content of phospholipid in the antarctic krill oil into the antarctic krill oil, heating while stirring for 30-120 min to 45-70 ℃, cooling, standing, and removing triglyceride through sedimentation separation or centrifugal separation to obtain the antarctic krill oil phospholipid solution; wherein the hydration solution contains 1.5 to 6 mass percent of citric acid;
(13) preparing oral liquid: adding 4-6 times of purified water into the Antarctic krill oil phospholipid solution, adding a flavoring agent with the mass ratio of the Antarctic krill oil phospholipid solution being 2-3%, adjusting the pH value to be neutral, and homogenizing under high pressure to obtain the oral liquid.
2. The euphausia superba oil phospholipid oral liquid with high EPA/DPA content according to claim 1, wherein the complex enzyme preparation in the step (4) is one or a mixture of protease, lipase and glucanase.
3. The euphausia superba oil phospholipid oral liquid with high EPA/DPA content according to claim 1, wherein the mass ratio of the protease, the lipase and the glucanase is 3:1: 1.
4. The euphausia superba oil phospholipid oral liquid with high EPA/DPA content according to claim 1, wherein the protease is one or a mixture of pepsin, neutral protease, bromelain, trypsin, papain and flavourzyme.
5. The euphausia superba oil phospholipid oral liquid with high EPA/DPA content according to claim 1, wherein the lipase is one or more of Candida esterase, Aspergillus esterase, Pseudomonas esterase and Rhizopus esterase.
6. The euphausia superba oil phospholipid oral liquid with high EPA/DPA content according to claim 1, wherein the lipase is a mixture of candida esterase and pseudomonas esterase, and the mass ratio of the lipase to the candida esterase to the pseudomonas esterase is 2: 1.
7. The euphausia superba oil phospholipid oral liquid with high EPA/DPA content as claimed in claim 1, wherein the composite microbial agent in step (5) is a mixed microbial agent of beer yeast, bacillus subtilis and bacillus megaterium, and the mass ratio of the composite microbial agent to the bacillus megaterium is 3:2: 1.
8. The euphausia superba oil phospholipid oral liquid with high EPA/DPA content as claimed in claim 1, wherein the ventilation rate of the aerobic fermentation process in the step (5) is 0.2-0.3 m3/m3.min。
9. The euphausia superba oil phospholipid oral liquid with high EPA/DPA content as claimed in claim 1The method is characterized in that the preparation method of the beer yeast seed liquid comprises the following steps: under the aseptic operation condition, two rings of strains are picked from the inclined plane of the yeast YDP by using an inoculating ring, inoculated into a 500mL triangular flask containing 300mLPDA liquid culture medium, subjected to shaking culture at the temperature of between 28 and 32 ℃ and at the speed of 140r/min for 24 hours, and then inoculated into a seed tank for expanded culture according to the process to prepare the yeast seed liquid, wherein the effective viable count of the seed liquid is required to be more than or equal to 109cfu/mL; the preparation method of the seed liquid of the bacillus subtilis and the bacillus megaterium comprises the following steps: under the aseptic condition, LB culture medium is adopted to culture for 24 hours under the condition of 28-32 ℃ to prepare liquid bacillus subtilis and bacillus megatherium seed liquid, and the effective viable count of the seed liquid is required to be more than or equal to 109cfu/mL。
10. The euphausia superba oil phospholipid oral liquid with high EPA/DPA content according to claim 1, wherein the sweetener is one or more of trehalose, xylitol, sorbitol, mannitol, fructose syrup and maltose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010453551.9A CN111588037A (en) | 2020-05-26 | 2020-05-26 | Euphausia superba oil phospholipid oral liquid with high EPA/DPA (eicosapentaenoic acid/docosahexaenoic acid) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010453551.9A CN111588037A (en) | 2020-05-26 | 2020-05-26 | Euphausia superba oil phospholipid oral liquid with high EPA/DPA (eicosapentaenoic acid/docosahexaenoic acid) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111588037A true CN111588037A (en) | 2020-08-28 |
Family
ID=72180764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010453551.9A Pending CN111588037A (en) | 2020-05-26 | 2020-05-26 | Euphausia superba oil phospholipid oral liquid with high EPA/DPA (eicosapentaenoic acid/docosahexaenoic acid) |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111588037A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115873656A (en) * | 2023-02-03 | 2023-03-31 | 山东康境海洋生物工程有限公司 | Method for extracting krill oil with high EPA/DHA content |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108179053A (en) * | 2018-01-26 | 2018-06-19 | 日照职业技术学院 | A kind of preparation method of high quality Antarctic krill oil |
| CN109198042A (en) * | 2018-10-22 | 2019-01-15 | 辽渔南极磷虾科技发展有限公司 | A kind of high EPA/DHA type antarctic krill oil phosphatide oral liquid and preparation method thereof |
| CN110574930A (en) * | 2019-08-02 | 2019-12-17 | 青岛浩大生物科技工程有限责任公司 | novel process for high-value utilization of euphausia superba |
| CN110663803A (en) * | 2019-11-01 | 2020-01-10 | 付鹏磊 | Euphausia superba oil polypeptide biological product capable of benefiting spleen and invigorating stomach |
-
2020
- 2020-05-26 CN CN202010453551.9A patent/CN111588037A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108179053A (en) * | 2018-01-26 | 2018-06-19 | 日照职业技术学院 | A kind of preparation method of high quality Antarctic krill oil |
| CN109198042A (en) * | 2018-10-22 | 2019-01-15 | 辽渔南极磷虾科技发展有限公司 | A kind of high EPA/DHA type antarctic krill oil phosphatide oral liquid and preparation method thereof |
| CN110574930A (en) * | 2019-08-02 | 2019-12-17 | 青岛浩大生物科技工程有限责任公司 | novel process for high-value utilization of euphausia superba |
| CN110663803A (en) * | 2019-11-01 | 2020-01-10 | 付鹏磊 | Euphausia superba oil polypeptide biological product capable of benefiting spleen and invigorating stomach |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115873656A (en) * | 2023-02-03 | 2023-03-31 | 山东康境海洋生物工程有限公司 | Method for extracting krill oil with high EPA/DHA content |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2010027117A1 (en) | Preparation method of gaba by fermentation of seaweed | |
| CN106581083A (en) | Extraction method for ganoderma lucidum components, biological feed and preparation method thereof | |
| KR101207899B1 (en) | The producing process of functional and fermented material containing taurine and GABA by fermentation with oyster | |
| KR101158448B1 (en) | The producing process of functional and fermented material containing high-concentration GABA by fermentation with yeast extract | |
| CN117568176B (en) | DHA extraction process based on microalgae extraction | |
| CN110241162A (en) | A kind of no fishy smell low molecular weight oyster peptide and its application | |
| CN101434981B (en) | Method for preparing vegetable seed peptide with single bioactivity by microbial solid state fermentation | |
| BE1026585B1 (en) | PROCESS AND APPLICATION FOR THE PREPARATION OF A MEDICAL FOOD RAW MATERIAL FOR MALIGNANT TUMORS OF FERMENTED VARECH USING PROBIOTICS | |
| CN110574930A (en) | novel process for high-value utilization of euphausia superba | |
| CN102586378A (en) | Method for extracting substances from fermented shrimp head shells | |
| CN110663803A (en) | Euphausia superba oil polypeptide biological product capable of benefiting spleen and invigorating stomach | |
| CN101215595A (en) | Method for extracting astaxanthin, protein and chitin from shrimp shells by using microorganisms | |
| CN1944626A (en) | Microbial bacteria for preparing ginkalide by microbial fermenting and method for preparing ginkalide | |
| CN113336734B (en) | Method for extracting procyanidine from aronia melanocarpa fruits | |
| CN111588037A (en) | Euphausia superba oil phospholipid oral liquid with high EPA/DPA (eicosapentaenoic acid/docosahexaenoic acid) | |
| CN108203729B (en) | Preparation method of kelp antioxidant peptide | |
| CN104498372A (en) | Fusarium oxysporum BM201, compound pectinase produced by fusarium oxysporum BM201 and preparation method and application of compound pectinase | |
| KR101017315B1 (en) | Fermented Maca composition and preparation method thereof | |
| CN103613494B (en) | Take Monascus anka Nakazawa et sato filament as technique and the production method that raw material extracts ubiquinone 10 | |
| CN116355816A (en) | Microorganism of fermented samara oil seed and blood lipid reducing composition thereof | |
| CN113957109B (en) | Industrial green production process of polystictus glycopeptide | |
| CN111607460A (en) | Preparation method of nutritional and fishy smell-free euphausia superba oil | |
| CN115595332A (en) | Method for preparing tremella fermentation liquor by combining compound enzyme with microbial fermentation | |
| AU2020102037A4 (en) | A method of efficiently increasing the alpha-glucosidase inhibitor content in fresh mulberry leaves by the solid-state fermentation | |
| CN111518860B (en) | Preparation method of cowberry fruit extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200828 |